CompletedPhase 4ACTRN12605000663651

Pravastatin for Hyperlipidaemia in HIV.

A Randomised, Double-blind Study of Pravastatin for the Treatment of Hyperlipidaemia in Patients with HIV

Sponsor

The University of New South Wales

Enrollment

40 participants

Start Date

Jul 12, 2002

Study Type

Interventional

Conditions

Lipodystrophy Lipid metabolism Glucose metabolism HIV

Summary

This study is a randomised, placebo-controlled study of the effect of treatment with the HMG-CoA reductase inhibitor, pravastatin, in HIV-infected, protease inhibitor treated patients with high serum cholesterol. We hypothesise that pravastatin will result in greater reductions in cholesterol than placebo when used in conjunction with appropriate dietary advice.

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests whether pravastatin can safely lower high cholesterol in people living with HIV who are taking protease inhibitor medications. Adults aged 18 and older who are HIV-positive with high cholesterol may be eligible. Participants would take pravastatin for 16 weeks and have regular blood tests to check cholesterol levels and overall health.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

This study is a randomised, placebo-controlled study of the effect of 12 weeks treatment with the HMG-CoA reductase inhibitor, pravastatin, in HIV-infected, protease inhibitor treated patients with high serum cholesterol. We hypothesise that pravastatin will result in greater reductions in cholesterol than placebo when used in conjunction with appropriate dietary advice.